Psyence Group Inc

Canadian Securities Exchange:PSYGCanadaView on OTC Pink - Current Information

Oct 31, 2024

Show headlines and story abstract

• Psyence Group Announces Closing of Previously Announced Disposal of its Stake in PsyLabs, from 9:30AM ET on Thursday Oct 31, 2024 by Dow Jones

  9:30AM ET on Thursday Oct 31, 2024 by Dow Jones
  Companies Mentioned: PSYG, PBM
  
  Neither of the parties referenced in this news release make any medical, treatment or health benefit claims about the proposed products. The U.S. Food and Drug Administration, Health Canada or other similar regulatory authorities have not evaluated claims regarding psilocybin, psilocybin analogues, or other psychedelic compounds or nutraceutical products. The efficacy of such products has not been confirmed by approved research. There is no assurance that the use of psilocybin, psilocybin analogues, or other psychedelic compounds or nutraceuticals can diagnose, treat, cure or prevent any disease or condition. Vigorous scientific research and clinical trials are needed. Neither of the parties referenced in this news release has conducted clinical trials for the use of the proposed products. Any references to quality, consistency, efficacy, and safety of potential products do not imply that any of the parties referenced in this news release verified such in clinical trials or that such parties will complete such trials. If the parties cannot obtain the approvals or research necessary to commercialize its business, it may have a material adverse effect on such parties' performance and operations.
  

• Press Release: Psyence Biomedical Announces Closing of Previously Announced Acquisition of Psyence Group's Stake in PsyLabs, from 7:30AM ET on Thursday Oct 31, 2024 by Dow Jones

  7:30AM ET on Thursday Oct 31, 2024 by Dow Jones
  Companies Mentioned: PSYG, PBM